The emergence of the Sudan strain of Ebola virus in Uganda prompted a rush to get vaccine candidates ready. Expectations are it will be needed in the future.

Two vaccines are poised for delivery against this old foe. What will it take for them to change the field?

Chris Beyrer, director of the Duke Global Health Institute and a renowned epidemiologist, discusses the monkeypox outbreak and the U.S. response.

HIV cure researchers are energized by news of another case of remission and the development of new tools that could help researchers evaluate how well other cure strategies are working.

Therapeutic antibodies against SARS-CoV-2 were developed faster than any other intervention, but their use remains limited. What lessons are there for the development of other monoclonal antibody products, including those for HIV?

An interview with Bali Pulendran on how adjuvants might extend the durability of mRNA-based vaccine protection.

Clinical research data is precious. The IAVI DataSpace platform seeks better ways to store, manage, and share this information securely so it can be used to advance medical research.

With pluck, persistence, and scientific prowess, more countries are gearing up to develop and produce the vaccines of the future.

COVID-19 has inspired many books about pandemic prevention, but reports show the world isn’t any better prepared today than it was before.

Scientists explain why a cytomegalovirus-vectored vaccine candidate, nearly 20 years in the making, produces promising results in monkeys. Will the same be true in humans?